-

Bristol Myers Squibb to Participate in the Bernstein 41st Annual Strategic Decisions Conference

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in the Bernstein 41st Annual Strategic Decisions Conference on Wednesday, May 28, 2025.

The company will take part in a fireside chat beginning at 3:30 p.m. ET.

Investors and the general public are invited to listen to the session by visiting http://investor.bms.com. An archived edition of the session will be available following its conclusion.

About Bristol Myers Squibb: Transforming Patients’ Lives Through Science

At Bristol Myers Squibb, our mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. We are pursuing bold science to define what’s possible for the future of medicine and the patients we serve. For more information, visit us at BMS.com and follow us on LinkedIn, X, YouTube, Facebook and Instagram.

corporatefinancial-news

Contacts

Media Relations:
media@bms.com

Investor Relations:
investor.relations@bms.com

Industry:

Bristol Myers Squibb

NYSE:BMY
Release Summary
Bristol Myers Squibb to Participate in the Bernstein 41st Annual Strategic Decisions Conference
Release Versions
English

Contacts

Media Relations:
media@bms.com

Investor Relations:
investor.relations@bms.com

More News From Bristol Myers Squibb

Bristol Myers Squibb to Present Data at ASCO® 2025 Highlighting Differentiated Research Platform of Oncology Treatments and Innovative Research Pipeline

PRINCETON, N.J.--(BUSINESS WIRE)--BMS to Present Data at ASCO® 2025 Highlighting Differentiated Research Platform of Oncology Treatments and Innovative Research Pipeline...

Bristol Myers Squibb Receives European Commission Approval for Perioperative Regimen of Neoadjuvant Opdivo® (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo for Resectable, High-Risk Non-Small Cell Lung Cancer with PD-L1 Expression ≥1%

PRINCETON, N.J.--(BUSINESS WIRE)--BMS Receives European Commission Approval for Perioperative Regimen of Neoadjuvant Opdivo and Chemotherapy Followed by Adjuvant Opdivo for......

Bristol Myers Squibb Appoints Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Appoints Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer...
Back to Newsroom